The overall goal of the University of Kansas Alzheimer's Disease Core Center (KU ADCC) Neuromaging Core is to enhance the neuroimaging infrastructure and facilitate increased research in aging and Alzheimer's disease for researchers at the University of Kansas and nearby institutions. The Neuroimaging Core builds on the established resources of the (i) KU Hoglund Brain Imaging Center that brings together, in a specialized research building, a unique array of human (3 Tesla) and animal (9.4 Tesla) MRI and cortical (151 channel) and fetal (83 channel) magnetoencephalography (MEG), and the (ii) KU Hospital that provides positron emission tomography as well as a strong faculty of imaging scientists with outstanding experience across the modalities. Accordingly, the Neuroimaging Core is ideally resourced to support current and future investigators who use imaging as a research tool. This goal will be achieved through three specific aims that provide (i) state-of-the-art imaging facilities and professional neuroimaging support, (ii) advanced education in imaging sciences and (iii) novel imaging approaches to AD investigators of the University of Kansas, the state of Kansas, and the Kansas City metropolitan area.
The Specific Aims of the KU ADCC Neuroimaging Core are Aim 1. Provide an integrated imaging environment with advanced scientific support and subsidized scans for AD research Aim 2. Provide advanced training, and education in imaging for ADCC investigators.
Aim 3. Develop novel imaging techniques for studies in AD.

Public Health Relevance

Neuroimaging provides a non-invasive means to measure structure and function of the living human brain. The Neuroimaging Core will support scientists investigating Alzheimer's and other neurodegenerative diseases of aging by providing access to state-of-the-art imaging, education and training in imaging modalities, and novel imaging methods.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG035982-03
Application #
8501218
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
3
Fiscal Year
2013
Total Cost
$75,228
Indirect Cost
$25,075
Name
University of Kansas
Department
Type
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Cirstea, Carmen M; Lee, Phil; Craciunas, Sorin C et al. (2018) Pre-therapy Neural State of Bilateral Motor and Premotor Cortices Predicts Therapy Gain After Subcortical Stroke: A Pilot Study. Am J Phys Med Rehabil 97:23-33
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Besser, Lilah; Kukull, Walter; Knopman, David S et al. (2018) Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 32:351-358
Morris, Jill K; Piccolo, Brian D; Shankar, Kartik et al. (2018) The serum metabolomics signature of type 2 diabetes is obscured in Alzheimer's disease. Am J Physiol Endocrinol Metab 314:E584-E596
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104

Showing the most recent 10 out of 333 publications